← Back to Clinical Trials
Recruiting NCT07152132

NCT07152132 SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07152132
Status Recruiting
Phase
Sponsor Minia University
Condition Glaucoma, Open Angle
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-07-20
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
TrabeculectomySlow coagulation trans-scleral cyclophotocoagulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-07-20 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

cyclodiode versus trabeculectomy with MMC in pseudophakic patients.

Eligibility Criteria

Inclusion Criteria: * 1\. Patients above 40 years old. 2\. POAG who underwent previous uncomplicated cataract surgery with intraocular lens implantation. 3\. Pseudophakic patients with medically uncontrolled glaucoma in spite of the use of two anti-glaucoma medications or intolerance to medical therapy. 4\. Visual field defects in both the superior and inferior hemi-fields outside the central 5 degrees of fixation. 5\. Mean deviation on perimetry ranges between -6 dB and -12 dB Exclusion Criteria: * 1\. Patients with history of previous glaucoma surgery. 2. Patients who have used topical steroids within the last three months. 3. Patients with significant media opacity, such as corneal opacity, that obstructs fundoscopic examination. 4\. Patients with ocular diseases as uveitis. 5. Patients with severe ocular surface disorders as ocular cicatricial pemphigoid. 6\. Aphakic patients. 7. Ocular interventions apart from YAG posterior capsulotomy.

Contact & Investigator

Central Contact

Hazem M Abdelaziz, Master

✉ hazem.m.abdelaziz@mu.edu.eg

📞 01010045499

Principal Investigator

Ahmed M Eid, MD

STUDY DIRECTOR

Minia University Hospital

Frequently Asked Questions

Who can join the NCT07152132 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying Glaucoma, Open Angle. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07152132 currently recruiting?

Yes, NCT07152132 is actively recruiting participants. Contact the research team at hazem.m.abdelaziz@mu.edu.eg for enrollment information.

Where is the NCT07152132 trial being conducted?

This trial is being conducted at Minya, Egypt.

Who is sponsoring the NCT07152132 clinical trial?

NCT07152132 is sponsored by Minia University. The principal investigator is Ahmed M Eid, MD at Minia University Hospital. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology